Sinovac Filed Its Annual Report on Form 20-F for 2009

BEIJING, April 16 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading China-based vaccine manufacturer, announced today it filed its annual report on Form 20-F for the fiscal year ended December 31, 2009 with the Securities and Exchange Commission on April 16, 2010. The annual report on Form 20-F can be accessed on Sinovac's website at http://www.sinovac.com/Investors/SECFilings/ . Sinovac will provide a hard copy of the annual report containing its audited consolidated financial statements, free of charge, to its shareholders upon request.

About Sinovac

Sinovac Biotech Ltd. is a China-based biopharmaceutical company that focuses on the research, development, manufacture and commercialization of vaccines that protect against human infectious diseases. Sinovac's commercialized vaccine products include Healive(R) (hepatitis A), Bilive(R) (combined hepatitis A and B), Anflu(R) (seasonal influenza), Panflu(TM) (pandemic influenza (H5N1)), and Panflu.1(TM) (pandemic influenza A (H1N1)). Sinovac is developing vaccines for enterovirus 71, universal pandemic influenza, pneumococcal infection, Japanese encephalitis, and human rabies. Its wholly owned subsidiary, Tangshan Yian, is conducting field trials for independently developed inactivated animal rabies vaccines.

For further information, please contact:

Sinovac Biotech Ltd.

Helen G. Yang

Tel: +86-10-8289-0088 x9871

Fax: +86-10-6296-6910

Email: info@sinovac.com

Investors:

Amy Glynn/Stephanie Carrington

The Ruth Group

Tel: +1-646-536-7023/7017

Email: aglynn@theruthgroup.com

scarrington@theruthgroup.com

Media

Janine McCargo

The Ruth Group

Tel: +1-656-536-7033

Email: jmccargo@theruthgroup.com